Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Novartis (NVS) announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, ...

Novartis to buy Boston-based clinical-stage biopharma company Anthos Therapeutics for up to $3.1 billion: Basel Tuesday, February 11, 2025, 17:45 Hrs [IST] Novartis announced that ...

Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues ...

Donald Trump ran on the rising price of eggs, which he blamed on President Joe Biden. He shouldn't cut off funding to the ...

IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune-mediated diseases, today ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

A dairy worker in Nevada has been confirmed to be infected by a new bird flu strain found to be spreading among cows in the ...